Skip to main content
TipRanks
Go Ultimate75% OFF

Lincoln Pharmaceuticals Ltd (LINCOLN) AI Stock Analysis

1 Followers
IN:LINCOLN

Lincoln Pharmaceuticals Ltd

(NSE:LINCOLN)

Select Model
Rating:66Neutral
Price Target:INR 553.00â–²(5.45% Upside)
Action:downgraded
Date:10/30/26

Robust financial health led by a strong low-debt balance sheet and growth, plus attractive valuation, are the primary drivers; weak technical momentum from downtrend indicators limits upside.

Positive Factors
Very Low LeverageExtremely low leverage materially limits debt-related financial risk and preserves flexibility for investment, product development, and market expansion. The growing equity base provides resilience if operating conditions weaken, while avoiding substantial interest burdens that could otherwise reduce future profitability.
Negative Factors
Margin CompressionBroad-based margin compression indicates that higher costs or a weaker product mix are absorbing part of the benefit from revenue growth. If this persists, earnings may expand more slowly than sales and the company could have less operating capacity to fund investment or withstand pricing pressure.

Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:LINCOLN-1.74%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 10.44B
Dividend Yield
0.34%
Average Volume (3M)
2,909
Price to Earnings (P/E)
10.8
Beta (1Y)
0.94
Revenue Growth
14.25%
EPS Growth
21.11%
Country
India
Employees
1,352
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model

Company Description

Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of med...

Lincoln Pharmaceuticals Ltd Financial Statement Overview

Summary

Strong balance sheet with minimal debt and growing equity, plus consistent revenue growth, offset by margin pressures and cash flow volatility.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.46B6.71B6.23B5.81B5.05B4.68B
Gross Profit3.28B2.20B3.32B2.97B2.59B2.46B
EBITDA1.29B1.31B1.24B1.34B1.12B1.05B
Net Income968.95M878.94M823.46M933.05M728.99M693.55M
Balance Sheet
Total Assets9.64B8.90B7.97B7.00B5.87B5.34B
Cash, Cash Equivalents and Short-Term Investments2.80B2.41B1.96B1.52B1.14B1.15B
Total Debt34.22M44.22M010.67M19.97M20.44M
Total Liabilities1.53B1.33B1.25B1.07B849.46M1.01B
Stockholders Equity8.12B7.58B6.72B5.93B5.02B4.33B
Cash Flow
Free Cash Flow0815.07M737.71M237.41M249.80M306.07M
Operating Cash Flow01.07B930.15M632.17M392.62M761.32M
Investing Cash Flow0-996.37M-789.47M-573.42M-366.43M-780.80M
Financing Cash Flow08.16M-64.02M-51.80M-45.01M-25.56M

Lincoln Pharmaceuticals Ltd Technical Analysis

Technical Analysis SentimentNeutral
Last Price524.40

Price Trends

50DMA563.84Negative
100DMA583.76Negative
200DMA594.10Negative

Market Momentum

MACD-11.68Negative
RSI45.74Neutral
STOCH68.37Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LINCOLN, the sentiment is Neutral. The current price of 524.40 is above the 20-day moving average (MA) of 521.32, below the 50-day MA of 563.84, and below the 200-day MA of 594.10, indicating a neutral trend. The MACD of -11.68 indicates Negative momentum. The RSI at 45.74 is Neutral, neither overbought nor oversold. The STOCH value of 68.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LINCOLN.

Lincoln Pharmaceuticals Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:LINCOLN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:JAGSNPHARMIN:JAGSNPHARM78OutperformINR 14.14B31.61―1.86%11.71%-26.92%
IN:VENUSREMIN:VENUSREM72OutperformINR 20.83B17.14―0.64%20.22%73.03%
IN:SYNCOMFIN:SYNCOMF69NeutralINR 19.83B23.29―0.47%0.44%48.60%
IN:LINCOLNIN:LINCOLN66NeutralINR 10.50B10.77―0.34%14.25%21.11%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:INDSWFTLABIN:INDSWFTLAB51NeutralINR 30.41B35.76――66.39%-72.31%
IN:WANBURYIN:WANBURY48NeutralINR 6.23B11.75――7.45%-6.56%

* General Sector Average

Performance Comparison

0%100%200%300%IN:LINCOLNIN:INDSWFTLABIN:JAGSNPHARMIN:SYNCOMFIN:VENUSREMIN:WANBURYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:LINCOLN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:LINCOLNLincoln Pharmaceuticals Ltd524.40-5.70-1.07%
IN:INDSWFTLABInd-Swift Laboratories Ltd.349.65252.75260.84%
IN:JAGSNPHARMJagsonpal Pharmaceuticals Ltd.214.106.092.93%
IN:SYNCOMFSyncom Formulation (India) Ltd.21.104.8029.46%
IN:VENUSREMVenus Remedies Limited1558.001006.06182.28%
IN:WANBURYWanbury Limited178.30-54.60-23.44%

Lincoln Pharmaceuticals Ltd Corporate Events

Lincoln Pharmaceuticals sets September 30 virtual AGM, proposes dividend and director re-appointments

Sep 5, 2026

Lincoln Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting for September 30, 2026, at 11:00 a.m. IST, to be conducted via video conferencing or other audio-visual means, with the registered office in Ahmedabad deemed as the venue. The...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026